RAVINA
30 november 2023
Studiecoördinator Dr. S.F. Oosting Afdeling Medische Oncologie Tel.: 050 3612821 (secretariaat Oncologie) E-mail: s.f.oosting@umcg.nl
Archief
PEAK
4 juli 2023
(Peak) A Phase 3 Randomized, Open-label, Multicenter Clinical Study of CGT9486+Sunitinib vs Sunitinib in Subjects with Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors Samenvatting Dit is een…
Potentia RL CBT307-1 (Imaging)
29 november 2022
A Phase I Study to Assess Biodistribution of 89Zr-CB307 in PSMA+ and PSMA-Tumour Lesions Eudractnummer: 2021-006256-13 CB307 is een trispecifieke Humabody® gericht op CD137; PSMA; en humaan serumalbumine…
CYCLONE-3
24 november 2022
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination with Abiraterone plus Prednisone in Men with High-Risk Metastatic Hormone-Sensitive Prostate Cancer EU trial number: 2022-500461-28-06 Samenvatting…
EORTC1976 – TOLERANCE
9 november 2022
A 3 arm randomized study on health-related quality of life of elderly patients with advanced soft tissue sarcoma undergoing doxorubicin every three weeks or doxorubicin weekly or cyclophosphamide…
INCB81776-101
13 oktober 2022
A Phase 1a/1b Study exploring the safety and tolerability of INCB081776 +/- retifanlimab in participants with advanced malignancies Protocol: INCB 81776-101 EudraCT Number: 2020-004867-26 Een Fase 1a/1b, open label…
INCB81776-101
10 oktober 2022
A Phase 1a/1b Study exploring the safety and tolerability of INCB081776 +/- retifanlimab in participants with advanced malignancies Protocol: INCB 81776-101 EudraCT Number: 2020-004867-26 Een Fase 1a/1b, open label…
MK3475-C93
13 september 2022
A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in…
CEMangio
4 juli 2022
Behandeling met cemiplimab van patiënten met lokaal vergevorderd of gemetastaseerd secundair angiosarcoom. Eudractnummer: 2020-005465-13 Samenvatting In deze fase II studie kunnen patiënten met een lokaal vergevorderd of gemetastaseerd…
Ave-short-trial
11 mei 2022
Een nationaal, multicenter, niet-geblindeerde doelmatigheids studie waarbij zes maanden avelumab onderhoudsbehandeling wordt gegeven aan patienten met een lokaal gevorderd of gemetastaseerde urotheelcarcinoom zonder ziekteprogressie na minimaal 4 kuren…
R2810-ONC-ISA-1981
17 februari 2022
A Phase 2 Study of Cemiplimab, an Anti-PD-1 Monoclonal Antibody, and ISA101b Vaccine in Patients with Recurrent/Metastatic HPV16 Cervical Cancer who have Experienced Disease Progression after ≥First Line…
OncoLifeS Immunotherapie
13 januari 2022
HER2CLIMB-02
6 september 2021
Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer Protocolnummer: SGNTUC-016 Eudractnummer:…
Destiny-PanTumor02
15 juni 2021
A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02) Protocolnummer D967VC00001…
M15-913
12 april 2021
An Open Label Phase 1, First-In-Human Study of TRAIL Receptor Agonist ABBV-621 in Subjects with Previously-Treated Solid Tumors and Hematologic Malignancies. M15-913 Protocolnummer: M15-913 Eudract nummer: 2016-003887-37 METc…
GALLOP-11
GALLOP-11
GALLOP-11
Validation of mutation analysis in circulating tumour DNA with a ddPCR assay as diagnostic and follow-up tool for patients with a KIT exon 11 mutated GIST: GALLOP-11. Protocolnummer:…
GALLOP-11
EORTC 1403 / rEECur
International randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma Eudractnummer: 2014-000259-99 Dit is een prospectief, multicenter, gerandomiseerd en open-label fase II/fase…